Table 2.
Summary of time-varying characteristics over all study visits
| Mean (SD) | Range | |
|---|---|---|
| CRP, mg/dl | 0.48 (1.48) | (0.01–12.60) |
| ESR, mm/h | 15.14 (44.05) | (1–120) |
| Tender joint count | 0.33 (0.92) | (0–6) |
| Swollen joint count | 0.41 (1.19) | (0–8) |
| Patient’s global assessment, VAS, mm | 7.73 (14.57) | (0–100) |
| DAS28-ESR | 1.87 (0.91) | (0.00–4.75) |
| Health Assessment Questionnaire | 0.25 (0.50) | (0.00–2.88) |
| Multi-biomarker disease activity | 23.23 (10.75) | (13–49) |
| Dose percentage (ratio of the full dosage) | 0.67 (0.29) | (0.00–1.00) |
| Relative week of visit (baseline visit is week 0) | 23.81 (17.53) | (0–59) |
| BMI, kg/m2 | 25.19 (3.86) | (17.5–39.45) |
| Dose percentage change* | −0.06 (0.27) | (−1.0–1.00) |
| Previous flare indicator (year/n) | 0.23 (0.42) | (0.00–1.00) |
BMI body mass index, CRP C-reactive protein, DAS-28 Disease Activity Score 28 joints, ESR erythrocyte sedimentation rate
*Current dose percentage – previous dose percentage